NME/NM23 family member 8Genealiases: CILD6 · DNAI8 · HEL-S-99 · NDK8 · NM23-H8 · SPTRX2
Q-omics provides the consensus-scored NME8 profile across patient tissues and cancer cell-line models. NME8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NME8 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NME8 RNA expression shows 15,076 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where NME8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME8 survival associations across molecular data types. NME8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME8 RNA expression–survival associations across cancer types. High NME8 expression shows unfavorable associations in KIRC, LGG and OV, but favorable associations in SKCM, HNSC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NME8 RNA expression.
This table summarizes NME8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NME8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME8 shows lower tumor expression in LUSC and higher tumor expression in KIRC, THCA, KIRP, BRCA and STAD. The KIRC box plot shows higher NME8 RNA expression in tumor versus normal tissue (log2 FC = +0.493, t-test p < 0.001).
This table shows molecular features associated with NME8 in patient tissues and cancer cell lines. In patient samples, NME8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NME8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
